There were however many other significant associations involving TP53 status, cancer driver gene mutations (or CNA) and activity of drugs (listed in Additional file 4: Data S7), for example the association between PIK3R1 mutations and sensitivity to MET inhibitors (Additional file 1: Fig. S11c). This evidence concerns the gene TP53 and cancer.